Project BioShield may soon be gutted; Novartis vet heads to Amgen; Merck KGaA selects chief for new division;

 @FierceBiotech: TheStreet tracks the top 10 clinical trials to watch. Report | Follow @FierceBiotech

 @JohnCFierce: One of the biggest things going on in Alzheimers's right now is Avid's new diagnostic test. This is a game changer. Report | Follow @JohnCFierce

> The four-year-old, $5.6 billion Project BioShield is facing the budget axe. Story

> McKinsey veteran and Novartis CFO Jonathan Peacock has been named CFO at the biotech giant Amgen. He's replacing Michael Kelly. Report

> Watson Pharmaceuticals has forged a pact with Itero Biopharmaceuticals to develop and commercialize a biosimilar molecule for the treatment of female infertility. The program is currently in the preclinical stage. Release

> Merck KGaA is naming the veteran Bernd Reckmann to run Millipore when it closes on the buyout deal this week. Story

> Shanghai Fosun Pharmaceutical and Spain's Grupo Chemo have agreed to provide $74 million for a new joint venture to develop new cancer therapies for the Chinese market. Report

> WILEX received a tender offer for a mandatory takeover bid by dievini Hopp BioTech Holding GmbH & Co. Release

> Amorflix Life Sciences nailed a $1 million upfront payment from Biogen Idec, which will use its antibodies in a treatment for ALS. Report

> San Diego-based Somaxon now has a contract sales force lined up to sell its sleep drug Silenor. Story

And Finally... Pfizer and the Samsung Medical Center will collaborate on new research work for liver cancer, analyzing the genetic profiles of patients in Korea. Report